NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

|Videos|March 7, 2023

Patient Case 1: A 71-year-old Woman with Newly Diagnosed mNSCLC

Author(s)Jason Porter, MD, Eric Vail, MD, Ana Velázquez Mañana, MD, MSc

Eric Vail, MD introduces a patient case, a 71-year-old Asian woman newly diagnosed with mNSCLC, followed by a focused discussion on how the panel would have approached biomarker testing and treatment initiation for the patient.

Episodes in this series

EP. 1 An Introduction to Biomarker Testing in Non-Small Cell Lung Cancer

EP. 1 An Introduction to Biomarker Testing in Non-Small Cell Lung Cancer

EP. 2 Analyzing the Relationship Between Biomarkers, Testing Rates, and Clinical Characteristics in Non-Small Cell Lung Cancer

EP. 2 Analyzing the Relationship Between Biomarkers, Testing Rates, and Clinical Characteristics in Non-Small Cell Lung Cancer

EP. 3 Available Biomarker Testing Modalities for Patients with mNSCLC

EP. 3 Available Biomarker Testing Modalities for Patients with mNSCLC

EP. 4 Clinical Experience with Coordinating Biomarker Testing for Patients with mNSCLC

EP. 4 Clinical Experience with Coordinating Biomarker Testing for Patients with mNSCLC

EP. 5 Patient Case 1: A 71-year-old Woman with Newly Diagnosed mNSCLC

EP. 5 Patient Case 1: A 71-year-old Woman with Newly Diagnosed mNSCLC

EP. 6 A Molecular Pathologist’s Insight into Institutional Best Practices for NSCLC Biomarker Testing

EP. 6 A Molecular Pathologist’s Insight into Institutional Best Practices for NSCLC Biomarker Testing

EP. 7 Challenges of Using Biomarker Testing in mNSCLC

EP. 7 Challenges of Using Biomarker Testing in mNSCLC

EP. 8 An Introduction to Three Real-World Analyses of Biomarker Testing Patterns in mNSCLC

EP. 8 An Introduction to Three Real-World Analyses of Biomarker Testing Patterns in mNSCLC

EP. 9 Overcoming Disparities in Biomarker Testing Use for mNSCLC

EP. 9 Overcoming Disparities in Biomarker Testing Use for mNSCLC

EP. 10 Patient Case 2: mNSCLC with an EGFR Exon 20 Insertion

EP. 10 Patient Case 2: mNSCLC with an EGFR Exon 20 Insertion

EP. 11 Managing Disease Progression in Patients with EGFR-mutated mNSCLC

EP. 11 Managing Disease Progression in Patients with EGFR-mutated mNSCLC

EP. 12 CHRYSALIS: Study Design and Key Results for Amivantamab in mNSCLC

EP. 12 CHRYSALIS: Study Design and Key Results for Amivantamab in mNSCLC

EP. 13 Safety and Efficacy Data for Mobocertinib in Patients with mNSCLC

EP. 13 Safety and Efficacy Data for Mobocertinib in Patients with mNSCLC

EP. 14 Data-Informed Insights on Second-line Treatment Selection for EGFR Exon 20-mutated mNSCLC

EP. 14 Data-Informed Insights on Second-line Treatment Selection for EGFR Exon 20-mutated mNSCLC

EP. 15 Patient Case 2: Second-line Treatment Selection and Adverse Event Management

EP. 15 Patient Case 2: Second-line Treatment Selection and Adverse Event Management

EP. 16 Insights into Third-Line Treatment Selection for Patients with EGFR Exon 20-mutated mNSCLC

EP. 16 Insights into Third-Line Treatment Selection for Patients with EGFR Exon 20-mutated mNSCLC

EP. 17 Key Takeaways Regarding Biomarker Testing for mNSCLC

EP. 17 Key Takeaways Regarding Biomarker Testing for mNSCLC

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

2 experts in this video

The Evolving MPN Landscape: Future Therapeutic Directions and Addressing Unmet Needs in Myelofibrosis and Polycythemia Vera

ByPankit Vachhani, MD,Raajit Rampal, MD, PhD

July 7th 2025

2 experts in this video

Emerging Treatment Paradigms: Rusfertide’s VERIFY Trial and Molecular Response-Guided Therapy in Advanced PV

ByPankit Vachhani, MD,Raajit Rampal, MD, PhD

July 7th 2025

2 experts in this video

Interferon Therapy Evolution: Clinical Applications and Paradigm Shifts in Polycythemia Vera Management

ByPankit Vachhani, MD,Raajit Rampal, MD, PhD

June 27th 2025

2 experts in this video

Management Strategies for Hydroxyurea-Resistant PV: Treatment Optimization and Evidence-Based Second-Line Selection

ByPankit Vachhani, MD,Raajit Rampal, MD, PhD

June 27th 2025

2 experts in this video

Response Assessment: Monitoring Parameters and Molecular Testing Integration

ByPankit Vachhani, MD,Raajit Rampal, MD, PhD

June 19th 2025

Latest CME

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Empire State Hematology & Oncology Society (New York)

Empire State Hematology & Oncology Society (New York)

3 Sessions are Available!

South Carolina Oncology Society

South Carolina Oncology Society

2 Sessions are Available!

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Aditya Bardia, MD, MPH, FASCO; Bachar Samra, MD

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Establishing the Rationale for ADC and ICI Combinations in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Sara A. Hurvitz, MD, FACP; Shaina Rozell, MD, MPH

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Kamel Abou Hussein, MD

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

August 24, 2026

24th Annual International Congress on the Future of Breast Cancer® East

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Project ECHO®: Advancing Care in Metastatic TNBC Through PD-L1–Informed Novel Frontline ADC Strategies

Project ECHO®: Advancing Care in Metastatic TNBC Through PD-L1–Informed Novel Frontline ADC Strategies

Webinar Series

Wisconsin Association of Hematology and Oncology

Wisconsin Association of Hematology and Oncology

2 Sessions are Available!

Tennessee Oncology Practice Society

Tennessee Oncology Practice Society

2 Session are Available!

Washington State Medical Oncology Society

Washington State Medical Oncology Society

2 Sessions are Available!

Colorado Oncology Society

Colorado Oncology Society

2 Sessions are Available!

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; Cynthia X. Ma, MD, PhD

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer

FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer

How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm

Why Awareness of Alcohol's Breast Cancer Risk Still Lags Decades Behind Tobacco

Ethical Challenges Behind Genome Sequencing and Precision Medicine